EUS‐guided antegrade biopsy for lower bile duct obstruction using novel biopsy device with tract dilatation system (with video)

2021 ◽  
Author(s):  
Takeshi Ogura ◽  
Junichi Kawai ◽  
Kyohei Nishiguchi ◽  
Yoshitaro Yamamoto ◽  
Kazuhide Higuchi
Keyword(s):  
Bile Duct ◽  
Bile Duct Obstruction ◽  
Duct Obstruction ◽  
Biopsy Device

Fibrolamellar carcinoma as a cause of bile duct obstruction

Pathology ◽  
1988 ◽  
Vol 20 (4) ◽  
pp. 326-331 ◽  
Author(s):  
Robert P. Eckstein ◽  
Christopher P. Bambach ◽  
Daniel Stiel ◽  
James Roche ◽  
Benjamin N. Goodman
Keyword(s):  
Bile Duct ◽  
Bile Duct Obstruction ◽  
Duct Obstruction ◽  
Fibrolamellar Carcinoma

scholarly journals Feasibility and Safety of Endoluminal Radiofrequency Ablation as a Rescue Treatment for Bilateral Metal Stent Obstruction Due to Tumor Ingrowth in the Hilum: A Pilot Study

2021 ◽  
Vol 10 (5) ◽  
pp. 952
Author(s):  
Hoonsub So ◽  
Chi Hyuk Oh ◽  
Tae Jun Song ◽  
Hyun Woo Lee ◽  
Jun Seong Hwang ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Bile Duct ◽  
Adverse Events ◽  
Bile Duct Obstruction ◽  
Metal Stents ◽  
Metal Stent ◽  
Duct Obstruction ◽  
Tumor Ingrowth ◽  
Malignant Bile Duct Obstruction ◽  
Hilar Bile Duct

Background. Radiofrequency ablation (RFA) is a palliative method known for its application in the endoscopic treatment of malignant bile duct obstruction. It may be a useful rescue method for metal stent malfunction caused by tumor ingrowth. This study aimed to examine the feasibility and safety of endoluminal RFA for occluded bilateral hilar metal stents due to tumor ingrowth in patients with malignant hilar bile duct obstruction. Methods: From March 2016 to June 2018, 11 patients with unresectable malignant hilar bile duct stricture with occluded bilateral hilar metal stents due to tumor ingrowth were enrolled. Endoluminal RFA was performed through a novel temperature-controlled catheter at a setting of 7 W power for 120 s with a target temperature of 80 °C via endoscopic retrograde cholangiopancreatography (ERCP). The patients’ demographics, clinical outcomes, and adverse events were investigated. Results: The median age was 64 (interquartile range, 54–72) years. All RFA procedures were successful. Clinical success was achieved in eight patients (72.7%). During the follow-up, eight patients (72.7%) showed stent dysfunction, and the median patency after RFA was 50 days (95% confidence interval (CI): 34–not available (NA)). All stent dysfunctions were successfully managed with ERCP. Ten patients died, and the median overall survival was 289 days (95% CI, 107–NA) from RFA to death. There was one case of mild abdominal pain after the procedure without serious adverse events. Conclusions: As a rescue therapy for occluded bilateral hilar metal stents due to tumor ingrowth, endoluminal RFA seemed to be safe and useful in selected patients.

scholarly journals Keratin 7 expression in hepatic cholestatic diseases

2021 ◽  
Author(s):  
S. Sakellariou ◽  
C. Michaelides ◽  
T. Voulgaris ◽  
J. Vlachogiannakos ◽  
E. Manesis ◽  
...  
Keyword(s):  
Bile Duct ◽  
Inverse Correlation ◽  
Bile Duct Obstruction ◽  
Hepatocyte Proliferation ◽  
Primary Biliary Cholangitis ◽  
Specific Marker ◽  
Ductular Reaction ◽  
Duct Obstruction ◽  
Cholestatic Diseases ◽  
Keratin 7

AbstractWe evaluated keratin 7 (K7) hepatocellular expression in 92 patients with common types of acute and chronic cholestatic diseases caused by bile duct obstruction/destruction or parenchymal lesions [acute hepatitis (n=20), mixed/pure cholestasis (n=16), primary biliary cholangitis-PBC (n=35), primary sclerosing cholangitis-PSC (n=10), vanishing bile duct syndrome (n=3), complete large bile duct obstruction due to space-occupying lesions (n=8)]. K7 immunohistochemical hepatocellular expression and ductular reaction (DR) were semi-quantitatively assessed. Results were correlated with liver enzyme serum levels, cholestasis type, histological features, hepatocellular Ki67 labelling index (LI) and HepPar1 expression. Hepatocellular K7 expression was detected in 87% (81/92) cases and in all cholestatic disease types with lowest incidence in pure/mixed cholestasis and highest in incomplete bile duct obstruction (iBDO), reaching 100% in PSC. K7-positive hepatocytes had low Ki67 LI (0-5%) retaining HepPar1 expression, irrespective of disease type. PSC cases had high K7 hepatocellular expression even with intact bile ducts, a feature that may aid differential diagnosis of cholestatic syndromes. K7 hepatocellular expression significantly correlated with cholestasis type, bile duct loss and fibrosis stage. It was higher in milder acute cholestatic hepatitis showing inverse correlation with hepatocyte proliferation and serum transaminase levels. In iBDO, younger age independently correlated with high K7 expression, while serum GGT levels showed a nearly significant correlation. Correlation with DR findings implied that K7-positive hepatocytes may result through metaplasia. In conclusion, K7 hepatocellular expression is a sensitive though non-specific marker of cholestasis. It may represent a cytoprotective reaction of resting hepatocytes in cholestasis of longer duration especially in younger patients.

Biliary endoprosthesis in bile duct obstruction secondary to hepatocellular carcinoma

1993 ◽  
Vol 18 (1) ◽  
pp. 70-75 ◽  
Author(s):  
Yoshitsugu Kubota ◽  
Toshihito Seki ◽  
Kohji Kunieda ◽  
Yoshitsugu Nakahashi ◽  
Kazuhiro Tani ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Bile Duct ◽  
Bile Duct Obstruction ◽  
Duct Obstruction ◽  
Biliary Endoprosthesis

A simultaneous endoscopic and laparoscopic approach for management of early iatrogenic bile duct obstruction

2014 ◽  
Vol 80 (3) ◽  
pp. 511-515 ◽  
Author(s):  
Aijaz A. Sofi ◽  
Jianlin Tang ◽  
Yaseen Alastal ◽  
Ali T. Nawras
Keyword(s):  
Bile Duct ◽  
Laparoscopic Approach ◽  
Bile Duct Obstruction ◽  
Duct Obstruction
Sign in / Sign up

Export Citation Format

Share Document